title: Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
abstract: This phase I/II study was designed to demonstrate the tolerance and the efficacy of a combination of pegylated interferon-α 2a to Imatinib mesylate (IM) 600mg daily in cytogenetically IM-resistant but in CHR chronic phase CML patients. The combination was generally well tolerated in the 15 evaluable patients. A significant reduction of the Ph1(+) BM metaphases was observed in these poor prognosis patients, with 2 long-term CCyR including 2 MMR. After a median follow-up of 43 months, 93% of patients are alive. The addition of PegIFNα2a to IM600 is feasible, and able to overcome resistance within this context.
authors.affiliation: Département d'hématologie clinique, hôpital Edouard Herriot, Lyon, France. franck-emmanuel.nicolini@chu-lyon.fr
authors.forename: Franck E
authors.initials: FE
authors.lastname: Nicolini
authors.forename: Sandrine
authors.initials: S
authors.lastname: Hayette
authors.forename: Laurence
authors.initials: L
authors.lastname: Legros
authors.forename: Philippe
authors.initials: P
authors.lastname: Rousselot
authors.forename: Frédéric
authors.initials: F
authors.lastname: Maloisel
authors.forename: Michel
authors.initials: M
authors.lastname: Tulliez
authors.forename: Agnès
authors.initials: A
authors.lastname: Guerci
authors.forename: Aude
authors.initials: A
authors.lastname: Charbonnier
authors.forename: Thomas
authors.initials: T
authors.lastname: Prébet
authors.forename: Françoise
authors.initials: F
authors.lastname: Rigal-Huguet
authors.forename: Kaddour
authors.initials: K
authors.lastname: Chabane
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Magaud
authors.forename: Carole
authors.initials: C
authors.lastname: Paillet
authors.forename: Christine
authors.initials: C
authors.lastname: Pivot
authors.forename: Mauricette
authors.initials: M
authors.lastname: Michallet
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D011994:Recombinant Proteins; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D000068877:Imatinib Mesylate; C100416:peginterferon alfa-2a